Literature DB >> 8280184

Exogenous glucocorticoids increase macrophage secretion of apo E by cholesterol-independent pathways.

S H Zuckerman1, G F Evans, L O'Neal.   

Abstract

Macrophage apo E synthesis and secretion has been previously demonstrated to be regulated by intracellular free cholesterol levels and is decreased by cytokines and other inflammatory stimuli associated with macrophage activation. In a recent study, the opposing effects of TGF beta and GM-CSF were reported with the former increasing and the latter decreasing apo E secretion and apo E mRNA levels. In an attempt to further understand the mechanisms by which TGF beta increased apo E expression in mouse peritoneal macrophages, the present study was performed to determine whether pharmacological agents could up-regulate apo E secretion by a mechanism independent of intracellular free cholesterol levels. Agents which resulted in increased apo E secretion were subdivided based on their effects on cAMP elevation. In addition to TGF beta, dexamethasone resulted in significant increases in apo E secretion. The 2-4-fold enhancement in apo E secretion by both TGF beta and dexamethasone occurred without concomitant changes in intracellular cAMP or free cholesterol. Other agents which increased apo E secretion included cholera toxin and 8-bromo-cAMP. While these agents did not affect intracellular cholesterol levels, cholera toxin did increase macrophage cAMP. The changes in apo E secretion by dexamethasone and 8-bromo-cAMP were associated with elevations in apo E mRNA. Dexamethasone-treated macrophages had 6-fold increases in apo E mRNA by 48 h when compared with control macrophages. Macrophages stimulated with 8-bromo-cAMP for 48 h demonstrated a more modest but statistically significant (P < 0.001) 2.2-fold increase. Similar effects of dexamethasone, cholera toxin, TGF beta, and 8-bromo-cAMP on apo E secretion were also apparent in macrophage-derived foam cells. In addition to increasing apo E secretion in macrophages and foam cells, dexamethasone and 8-bromo-cAMP inhibited the down-regulation of apo E secretion mediated by LPS and GM-CSF. Finally, the increased apo E secretion by exogenous glucocorticoids or TGF beta was not species specific as similar effects were observed in rabbit peritoneal macrophages. Therefore, while macrophage activation results in decreased apo E synthesis, macrophages exposed to anti-inflammatory agents including dexamethasone, TGF beta, or following cAMP elevation demonstrate increased apo E secretion by a cholesterol-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280184     DOI: 10.1016/0021-9150(93)90038-v

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Proteomic analysis of cerebrospinal fluid in canine cervical spondylomyelopathy.

Authors:  Paula Martin-Vaquero; Ronaldo C da Costa; Matthew J Allen; Sarah A Moore; Jeremy K Keirsey; Kari B Green
Journal:  Spine (Phila Pa 1976)       Date:  2015-05-01       Impact factor: 3.468

2.  Chronic administration of dexamethasone results in Fc receptor up-regulation and inhibition of class I antigen expression on macrophages from MRL/lpr autoimmune mice.

Authors:  S H Zuckerman; G F Evans; N Bryan
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

Review 3.  The key role of apolipoprotein E in atherosclerosis.

Authors:  Kirsty Greenow; Nigel J Pearce; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2005-04-13       Impact factor: 4.599

4.  Differential action of glucocorticoids on apolipoprotein E gene expression in macrophages and hepatocytes.

Authors:  Violeta Georgeta Trusca; Elena Valeria Fuior; Ioana Madalina Fenyo; Dimitris Kardassis; Maya Simionescu; Anca Violeta Gafencu
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

5.  Pharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs).

Authors:  Suzanne Zeitouni; Brian S Ford; Sean M Harris; Mandolin J Whitney; Carl A Gregory; Darwin J Prockop
Journal:  BMC Biotechnol       Date:  2008-09-29       Impact factor: 2.563

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.